Cardiac dysfunction in solid tumours: a neglected problem. A cardio-oncology scoping review
https://spcare.bmj.com/content/early/2023/11/24/spcare-2023-004440
"In conclusion: (1) There is evidence for cardiovascular dysfunction in patients with solid tumour malignancies, distinct from CTRCD. People with solid tumours have higher rates of cardiac disease, even when newly diagnosed and treatment naïve. (2) Abnormalities manifest mainly as cardiomyopathies, ANS dysfunction and raised biomarker levels and are associated with significant symptoms. (3) Treatment plans need to take account of these risks, and widen criteria for screening."
- Forums
- ASX - By Stock
- RAC
- Cardioprotection thread
Cardioprotection thread, page-2
-
- There are more pages in this discussion • 904 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.71 |
Change
0.010(0.59%) |
Mkt cap ! $299.0M |
Open | High | Low | Value | Volume |
$1.76 | $1.79 | $1.70 | $231.1K | 131.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9724 | $1.71 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.71 | 450 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9724 | 1.705 |
2 | 1509 | 1.700 |
1 | 4963 | 1.675 |
1 | 744 | 1.670 |
1 | 5361 | 1.660 |
Price($) | Vol. | No. |
---|---|---|
1.725 | 5101 | 2 |
1.730 | 4954 | 1 |
1.735 | 650 | 1 |
1.740 | 2236 | 1 |
1.760 | 650 | 1 |
Last trade - 12.31pm 02/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online